title: Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.
abstract: OBJECTIVE
  Treatment of patients with mucosal prostatic urethral transitional cell carcinoma (TCC) is controversial. In this study, we evaluated the outcome of patients with mucosal prostatic urethral TCC who were managed conservatively.
  
  
  METHODS
  The data of 290 consecutive male patients with superficial TCC of the bladder who were treated at our institution were reviewed. Median age was 63 years and median follow-up was 63 months. Initially, all patients with mucosal PU involvement without evidence of ductal and/or stromal involvement underwent intravesical BCG or Epirubicin therapy.
  
  
  RESULTS
  Nineteen patients (6.6%) had mucosal involvement of the prostatic urethra (PU) and concomitant multifocal TCC of the bladder. Of those, 12 patients (12/19, 4.2%) had macroscopic mucosal involvement of the PU, while the other 7 patients (7/19, 2.4%) had microscopic PU tumor. Seven of 12 patients who were treated with BCG and 2 of 7 patients who were treated with Epirubicin achieved complete response. Progression occurred in 3 patients who received BCG and no patients progressed in the Epirubicin group.
  
  
  CONCLUSIONS
  Prostatic urethral sampling should be considered necessary in intermediate and high risk patients with superficial TCC of the bladder. Intravesical therapy, especially with BCG seems to be an effective treatment alternative in the management of mucosal PU involvement.
authors.affiliation: Dokuz Eylul University School of Medicine, Department of Urology, Inciralti 35340 Izmir, Turkey. erdemcanda@yahoo.com
authors.forename: A Erdem
authors.initials: AE
authors.lastname: Canda
authors.forename: Emre
authors.initials: E
authors.lastname: Tuzel
authors.forename: M Ugur
authors.initials: MU
authors.lastname: Mungan
authors.forename: Kutsal
authors.initials: K
authors.lastname: Yorukoglu
authors.forename: Ziya
authors.initials: Z
authors.lastname: Kirkali
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D015251:Epirubicin / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000473:pathology; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014523:Urethral Neoplasms / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D015251:Epirubicin